Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of 3,3'-Diindolylmethane (BR-DIM) in Patients With Systemic Lupus Erythematosus (SLE)

NCT02483624 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT02483624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02483624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of 3,3'-Diindolylmethane (BR-DIM) in Patients With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Northwell Health
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2016
Completion date
January 31, 2016
Enrollment
6 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sle